Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.

The combination of tenofovir (TDF), emtricitabine (FTC, and nevirapine (NVP) is reccomended as fist-line treatment for antiretroviral-naive patients in some guidelines.
We conducted an open-label, randomized, controlled trial to compare elevations in the plasma cholesterol and triglyceride levels after TDF/FTC plus either NVP or atazanavir/ritonavir (ATV/r).
Risk of early virological failure was significantly higher in the nevirapine arm then in the ATV/r arm for both the intent-to-treat (P=0.021) and on-treatment (P=0.045) analyses, suggesting that TDF/FTC + NVP should be avoid if antiretroviral combinations that have been validated by randomized, controlled trials are available.